Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

4(80.0%)

Phase 4

1(20.0%)

5Total

Phase 3(4)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT01280981Phase 3Completed

A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding

Role: collaborator

NCT00366444Phase 3Completed

Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery

Role: lead

NCT01133873Phase 4Terminated

Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects

Role: lead

NCT00375934Phase 3Completed

Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery

Role: lead

NCT00655291Phase 3Completed

Efficacy of XP20B Following Bunionectomy Surgery

Role: lead

All 5 trials loaded